Table 2. Patient characteristics by ART use.
| Antiretroviral Status | ||||
| Characteristic | Overall | ART (n = 126) N1 (%) | No ART (n = 91) N1 (%) | p-value2 |
| Male | ||||
| 86 (55.8) | 49 (55.1) | 37 (56.9) | 0.82 | |
| Age (range 18–59) | ||||
| <18 | 1 (0.5) | 1(1.0) | 0 | 0.92 |
| 18–24 | 14 (7.6) | 7(6.9) | 7(8.3) | |
| 25–29 | 27 (14.6) | 16(15.8) | 11(13.1) | |
| 30–34 | 67 (36.2) | 34(33.7) | 33(39.3) | |
| 35–44 | 53 (28.7) | 31(30.7) | 22(26.2) | |
| 45+ | 23 (12.4) | 12(11.9) | 11(13.1) | |
| Median (IQR) | 32.9 (29.4–39.5) | 33.0 (29.5–39.5) | 32.1 (29.3–39.2) | |
| CD4 count | ||||
| >350 cells/µl | 13 (12.5) | 10(15.2) | 3(7.9) | 0.550 |
| 200–350 cells/µl | 3 (2.9) | 2(3.0) | 1(2.6) | |
| <200 cells/µl | 88 (84.6) | 54(81.8) | 34(89.5) | |
| Median (IQR) | 55.5 (21.0–123.5) | 53.5 (17–155) | 56 (23–94) | |
| TB Resistance Pattern | ||||
| ODR | 16 (7.4) | 15(11.9) | 1(1.1) | 0.001 |
| MDR | 119 (54.8) | 59 (46.8) | 60(65.9) | |
| XDR | 82 (37.8) | 52(41.3) | 30(33.0) | |
| Length of TB treatment | ||||
| Median Months (IQR) | 28.5 (10.8–45.8) | 31.9(15.2–45.8) | 22.5 (4.9–43.8) | 0.008 |
| Total Number of Drugs | ||||
| < = 4 | 61 (28.1) | 39(31.0) | 22(24.2) | 0.179 |
| 5 | 85 (39.2) | 52(41.3) | 33(36.3) | |
| > = 6 | 71 (32.7) | 35(27.8) | 36(39.6) | |
| Total Number of Effective Drugs3 | ||||
| < = 3 | 185 (85.3) | 112 (88.9) | 73(80.2) | 0.185 |
| 4 | 22 (10.1) | 10(7.9) | 12(13.2) | |
| >4 | 10 (4.6) | 4(3.2) | 6(6.6) | |
| ART Regimen Base | ||||
| NNRTI | – | 60(51.3) | – | – |
| PI | – | 26 (22.2) | – | – |
| NRTI | – | 31 (26.5) | – | – |
1
N's may not add up to total N because of missing values.
2
p-values of ART use vs. non-use comparisons based on the categorical version of variable are presented unless interpretation of p-value based on of continuous version differed.
3
Effective drug: Demonstrated susceptibility to drug by sputum culture.